Vimarsana
Biggest News Aggregation in the World

Page 3 - Double Blind Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Double Blind Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Double Blind Phase Today - Breaking & Trending Today

AUA 2021: State-of-the-art Lecture: First and Second Line Therapy in Advanced and Metastatic Bladder Cancer: A Changing Paradigm - Vimarsana News

AUA 2021: State-of-the-art Lecture: First and Second Line Therapy in Advanced and Metastatic Bladder Cancer: A Changing Paradigm

AUA 2021 First and Second Line Therapy in Advanced and Metastatic Bladder Cancer, metastatic urothelial cancer, MVAC chemotherapy, checkpoint immunotherapy, platinum-refractory advanced UC, Keynote-045 study, IMvigor130 trial, DANUBE trial, KEYNOTE-361 trial.

Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration - Vimarsana News

Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration

Share this article Share this article ZUG, Switzerland, May 4, 2021 /PRNewswire/ -- Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, today announces that it has entered into a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the protocol titled, "A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer (CATIQ P3)." Isoquercetin, the Company's le...

BioArctic : Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy - Vimarsana News

BioArctic : Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy

Message : Required fields Stockholm April 20, 2021 - BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Aβ Protofibril Antibody, in the peer-reviewed journal Alzheimer's Research & Therapy. The manuscript describes results from Study 201, a Phase 2b proof-of-concept study that explored the impact of treatment with lecanemab on reducing brain amyloid beta (Aβ) and clinical decline in patients with early Al...

Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy - Vimarsana News

Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy

Share this article Share this article STOCKHOLM, April 20, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Aβ Protofibril Antibody, in the peer-reviewed journal Alzheimer's Research & Therapy.  The manuscript describes results from Study 201, a Phase 2b proof-of-concept study that explored the impact of treatment with lecanemab on reducing brain amyloid beta (Aβ) and clinical decline in pa...